BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 20056345)

  • 1. 18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy.
    Schellenberg D; Quon A; Minn AY; Graves EE; Kunz P; Ford JM; Fisher GA; Goodman KA; Koong AC; Chang DT
    Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1420-5. PubMed ID: 20056345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy.
    Dholakia AS; Chaudhry M; Leal JP; Chang DT; Raman SP; Hacker-Prietz A; Su Z; Pai J; Oteiza KE; Griffith ME; Wahl RL; Tryggestad E; Pawlik T; Laheru DA; Wolfgang CL; Koong AC; Herman JM
    Int J Radiat Oncol Biol Phys; 2014 Jul; 89(3):539-46. PubMed ID: 24751410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of metabolic 18FDG-PET response on outcomes in patients with locally advanced pancreatic carcinoma treated with definitive concurrent chemoradiotherapy.
    Topkan E; Parlak C; Kotek A; Yapar AF; Pehlivan B
    BMC Gastroenterol; 2011 Nov; 11():123. PubMed ID: 22074002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer.
    Mahadevan A; Jain S; Goldstein M; Miksad R; Pleskow D; Sawhney M; Brennan D; Callery M; Vollmer C
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):735-42. PubMed ID: 20171803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer.
    Mahadevan A; Miksad R; Goldstein M; Sullivan R; Bullock A; Buchbinder E; Pleskow D; Sawhney M; Kent T; Vollmer C; Callery M
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e615-22. PubMed ID: 21658854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretreatment maximum standardized uptake value on 18F-fluorodeoxyglucose positron emission tomography is a predictor of outcome for stage I non-small cell lung cancer after stereotactic body radiotherapy.
    Tanaka H; Hayashi S; Hoshi H
    Asia Pac J Clin Oncol; 2016 Mar; 12(1):e113-7. PubMed ID: 24176011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maximum standardized uptake value on FDG-PET is a strong predictor of overall and disease-free survival for non-small-cell lung cancer patients after stereotactic body radiotherapy.
    Takeda A; Sanuki N; Fujii H; Yokosuka N; Nishimura S; Aoki Y; Oku Y; Ozawa Y; Kunieda E
    J Thorac Oncol; 2014 Jan; 9(1):65-73. PubMed ID: 24346094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer.
    Schellenberg D; Goodman KA; Lee F; Chang S; Kuo T; Ford JM; Fisher GA; Quon A; Desser TS; Norton J; Greco R; Yang GP; Koong AC
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):678-86. PubMed ID: 18395362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of maximum standardized uptake value (SUVmax) on 18F-FDG PET/CT in patients with locally advanced or metastatic pancreatic cancer.
    Moon SY; Joo KR; So YR; Lim JU; Cha JM; Shin HP; Yang YJ
    Clin Nucl Med; 2013 Oct; 38(10):778-83. PubMed ID: 24107806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Timing of fluorodeoxyglucose positron emission tomography maximum standardized uptake value for diagnosis of local recurrence of non-small cell lung cancer after stereotactic body radiation therapy.
    Tan D; Gill S; Loh N
    Cancer Med; 2020 Oct; 9(20):7469-7476. PubMed ID: 32846054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretreatment [18F]-fluoro-2-deoxy-glucose positron emission tomography maximum standardized uptake value as predictor of distant metastasis in early-stage non-small cell lung cancer treated with definitive radiation therapy: rethinking the role of positron emission tomography in personalizing treatment based on risk status.
    Nair VJ; MacRae R; Sirisegaram A; Pantarotto JR
    Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):312-8. PubMed ID: 24411602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of maximum standardized uptake value measured by pretreatment 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinoma.
    Cacicedo J; Fernandez I; Del Hoyo O; Navarro A; Gomez-Iturriaga A; Pijoan JI; Martinez-Indart L; Escudero J; Gomez-Suarez J; de Zarate RO; Perez JF; Bilbao P; Rades D
    Clin Transl Oncol; 2017 Nov; 19(11):1337-1349. PubMed ID: 28540535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic values of 18F-FDG PET/CT metabolic parameters and clinical figures in locally advanced pancreatic cancer underwent chemotherapy combined with stereotactic body radiation therapy.
    Zhang A; Ren S; Yuan Y; Li X; Zhu X; Jiang L; Li D; Zuo C
    Medicine (Baltimore); 2019 Mar; 98(13):e15064. PubMed ID: 30921238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.
    Herman JM; Chang DT; Goodman KA; Dholakia AS; Raman SP; Hacker-Prietz A; Iacobuzio-Donahue CA; Griffith ME; Pawlik TM; Pai JS; O'Reilly E; Fisher GA; Wild AT; Rosati LM; Zheng L; Wolfgang CL; Laheru DA; Columbo LA; Sugar EA; Koong AC
    Cancer; 2015 Apr; 121(7):1128-37. PubMed ID: 25538019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of preoperative fluorodeoxyglucose positron emission tomography/computed tomography in patients with potentially resectable pancreatic cancer.
    Omiya Y; Ichikawa S; Satoh Y; Motosugi U; Nakajima N; Onishi H
    Abdom Radiol (NY); 2018 Dec; 43(12):3381-3389. PubMed ID: 30043215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of pretreatment whole-tumor perfusion computed tomography and 18F-fluorodeoxyglucose positron emission tomography/computed tomography measurements on local control of non-small cell lung cancer treated with stereotactic body radiotherapy.
    Aoki M; Akimoto H; Sato M; Hirose K; Kawaguchi H; Hatayama Y; Seino H; Kakehata S; Tsushima F; Fujita H; Fujita T; Fujioka I; Tanaka M; Miura H; Ono S; Takai Y
    J Radiat Res; 2016 Sep; 57(5):533-540. PubMed ID: 27296251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formula corrected maximal standardized uptake value in FDG-PET for partial volume effect and motion artifact is not a prognostic factor in stage I non-small cell lung cancer treated with stereotactic body radiotherapy.
    Yamamoto T; Kadoya N; Shirata Y; Kaneta T; Koto M; Umezawa R; Ishikawa Y; Kubozono M; Sugawara T; Matsushita H; Abe K; Takeda K; Jingu K
    Ann Nucl Med; 2015 Oct; 29(8):666-73. PubMed ID: 26040413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy.
    Mellon EA; Jin WH; Frakes JM; Centeno BA; Strom TJ; Springett GM; Malafa MP; Shridhar R; Hodul PJ; Hoffe SE
    Acta Oncol; 2017 Mar; 56(3):391-397. PubMed ID: 27885876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of nodal maximum standardized uptake value of pretreatment [18F]fluorodeoxyglucose positron emission tomography imaging in patients with esophageal cancer.
    Yap WK; Chang YC; Tseng CK; Hsieh CH; Chao YK; Su PJ; Hou MM; Yang CK; Pai PC; Lin CR; Hsieh CE; Wu YY; Hung TM
    Dis Esophagus; 2017 Aug; 30(8):1-10. PubMed ID: 28575243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The maximum standardized uptake value (SUVmax) on FDG-PET is a strong predictor of local recurrence for localized non-small-cell lung cancer after stereotactic body radiotherapy (SBRT).
    Takeda A; Yokosuka N; Ohashi T; Kunieda E; Fujii H; Aoki Y; Sanuki N; Koike N; Ozawa Y
    Radiother Oncol; 2011 Nov; 101(2):291-7. PubMed ID: 21889224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.